Sequencing Explains 'Outlier' Patient Response to Everolimus, Shows Promise ... GenomeWeb Sequencing the genome of a cancer bladder patient who responded exceptionally well to a cancer drug that failed in most other patients in a clinical trial, researchers have identified mutations that might serve as predictors of sensitivity to the drug. |
